Literature DB >> 30231927

Oligodendrogliomas, IDH-mutant and 1p/19q-codeleted, arising during teenage years often lack TERT promoter mutation that is typical of their adult counterparts.

Julieann Lee1, Angelica R Putnam2, Samuel H Chesier3, Anuradha Banerjee4, Corey Raffel5, Jessica Van Ziffle1,6, Courtney Onodera1,6, James P Grenert1,6, Boris C Bastian1,6, Arie Perry1,5, David A Solomon7,8.   

Abstract

Entities:  

Keywords:  1p/19q-codeletion; CIC; FGFR1; IDH mutation; IDH1; Molecular neuro-oncology; Oligodendroglioma; Pediatric; TERT promoter; Teenager

Mesh:

Substances:

Year:  2018        PMID: 30231927      PMCID: PMC6145350          DOI: 10.1186/s40478-018-0598-x

Source DB:  PubMed          Journal:  Acta Neuropathol Commun        ISSN: 2051-5960            Impact factor:   7.801


× No keyword cloud information.
The genetic alterations that characterize oligodendroglial neoplasms have been defined over the past decade. In adults, oligodendrogliomas are genetically defined by the combination of IDH1 p.R132 or IDH2 p.R172 mutation, TERT promoter hotspot mutation (either c.-124C > T or c.-126C > T), and chromosomes 1p and 19q co-deletion, which is frequently accompanied by mutations involving CIC, FUBP1, TCF12, NOTCH1, and PIK3CA genes [2, 3, 7, 13, 21]. Oligodendrogliomas in children often lack the IDH mutation, TERT promoter mutation, and 1p/19q-codeletion that is observed in their adult counterparts [14, 20]. Instead, they most commonly harbor solitary pathogenic alterations in the FGFR1 oncogene that cause constitutive activation of the kinase domain via gene fusion, tandem duplication, or missense mutations that localize at one of two hotspots (p.N546 or p.K656) [18, 23]. To investigate the molecular pathogenesis of oligodendrogliomas arising during teenage years, we assembled a cohort of tissue specimens from three patients (Fig. 1a). The one male and two female patients ranged in age at time of initial surgery from 10-18 years. All patients presented with headaches that led to brain imaging, which demonstrated non-enhancing, T2-hyperintense masses centered in the frontal (n=2) or parietal (n=1) lobes (Fig. 1b). All cases were histologically characterized by an infiltrative glial neoplasm composed of cells with uniform round nuclei containing delicate chromatin (Fig. 1c). Mitoses were inconspicuous, and neither microvascular proliferation nor necrosis were present. Immunohistochemistry revealed that the tumor cells were OLIG2 positive, had intact/retained nuclear expression of ATRX protein, and showed only occasional positivity for p53 protein. The Ki-67 labeling index was uniformly low (less than 2%).
Fig. 1

Oligodendrogliomas, IDH-mutant and 1p/19q-codeleted, arising during teenage years often lack TERT promoter hotspot mutation. a, Table of the clinicopathologic features of the three teenagers with oligodendroglioma. b, Pre-operative magnetic resonance imaging for the three patients. c, Histology of the three tumors. Hematoxylin and eosin staining, 60× magnification. d, Snapshot from the Integrated Genome Viewer for the three oligodendrogliomas in teenagers demonstrating absence of the TERT promoter hotspot mutation seen in oligodendrogliomas, IDH-mutant and 1p/19q-codeleted, from adults

Genomic DNA was extracted from formalin-fixed, paraffin-embedded tumor tissue, and targeted capture-based next-generation DNA sequencing was performed as previously described using the UCSF500 Cancer Panel [8, 9, 11, 16, 17], which assesses approximately 500 cancer-associated genes for mutations, copy number alterations, and structural variants including gene fusions (Additional file 1: Table S1). All three cases demonstrated IDH mutation, with two harboring IDH2 p.R172K and one harboring IDH1 p.R132H (Additional file 1: Table S2 and Additional file 2: Fig. S1). Additionally, case #1 contained a damaging missense mutation in TP53 (p.R175H), which was present at a subclonal allele frequency (6%) relative to the IDH1 mutation (20%), indicating that it was only present in a subset of tumor cells. Case #3 additionally contained a truncating nonsense mutation in the CIC tumor suppressor gene (p.S349*). No pathogenic mutations were identified involving any of the other genes targeted for sequencing by this assay. Chromosomal copy number analysis revealed losses of 1p and 19q in all three cases, which uniformly involved the entire arms of these chromosomes. No other chromosomal gains, losses, or focal amplifications or deletions were identified in any of the tumors (Additional file 1: Table S3 and Additional file 2: Fig. S2). Notably, all three cases lacked mutation at either of the two hotspots in the promoter region of the TERT gene (Fig. 1d), and also did not harbor either TERT gene amplification or structural rearrangement within the 50 Kb of upstream sequence covered by this assay, where rearrangements are commonly found in high-risk neuroblastomas, chromophobe renal cell carcinomas, and IDH-wildtype glioblastomas lacking TERT promoter hotspot mutation [5, 6, 15, 22]. Oligodendrogliomas, IDH-mutant and 1p/19q-codeleted, arising during teenage years often lack TERT promoter hotspot mutation. a, Table of the clinicopathologic features of the three teenagers with oligodendroglioma. b, Pre-operative magnetic resonance imaging for the three patients. c, Histology of the three tumors. Hematoxylin and eosin staining, 60× magnification. d, Snapshot from the Integrated Genome Viewer for the three oligodendrogliomas in teenagers demonstrating absence of the TERT promoter hotspot mutation seen in oligodendrogliomas, IDH-mutant and 1p/19q-codeleted, from adults In order to further assess the frequency of TERT promoter mutation in IDH-mutant and 1p/19q-codeleted oligodendrogliomas in teenagers, we examined data from the four major pediatric low-grade glioma genomics studies published to date [1, 18, 19, 23]. Together, these four studies included only a single teenage patient with an oligodendroglioma, IDH-mutant and 1p/19q-codeleted, in which TERT promoter status had been assessed. This patient (SJLGG034 from the Zhang et al study, also labeled LGNT20 in the Qaddoumi et al study) was a 15 year old male with an oligodendroglioma that harbored IDH1 p.R132H mutation, multiple CIC mutations, 1p/19q-codeletion, and reportedly lacked TERT promoter mutation [18, 23]. We next examined data from the most recent glioma metagenomics study by The Cancer Genome Atlas Research Network that included 89 cases of oligodendroglioma, IDH-mutant and 1p/19q-codeleted, WHO grade II or III, in which TERT promoter status was reported [4]. 87 of these 89 cases (98%) reportedly harbored TERT promoter hotspot mutation and were all in adults (age range 20-75 years at diagnosis). Two of the 89 cases are reported to be TERT promoter wildtype, one in a teenager and one in an older adult. The first TERT promoter wildtype oligodendroglioma case (TCGA-DB-5278) was centered in the left frontal lobe of a 17 year old male who had presented with seizures, demonstrated WHO grade II histologic features, IDH1 p.R132H mutation, CIC mutation, 1p/19q-codeletion, and did not have TERT overexpression. The second TERT promoter wildtype oligodendroglioma case (TCGA-HT-8010) was in a 64 year old female, had WHO grade II histologic features, IDH mutation, NF1 mutation, 1p/19q-codeletion, and also did not have TERT overexpression. Thus, according to the latest published dataset from The Cancer Genome Atlas, TERT promoter mutation was present in 87/88 cases (99%) of IDH-mutant and 1p/19q-codeleted oligodendrogliomas in adults age 20+ years at time of diagnosis. In contrast, TERT promoter mutation was present in 0/5 cases (0%) of IDH-mutant and 1p/19-codeleted oligodendrogliomas in teenagers, including the three patients from our cohort, one patient from Zhang et al, and one patient from The Cancer Genome Atlas. Together, these findings suggest that oligodendrogliomas arising during teenage years are genetically distinct from their adult counterparts based on the absence of TERT promoter mutation. Though telomere maintenance has been proposed as a requirement for gliomagenesis in adults [10, 12], it does not appear to be necessary in oligodendrogliomas, IDH-mutant and 1p/19q-codeleted, in teenagers. We speculate that this may be due to the low number of cell divisions that have taken place in oligodendrogliomas arising in teenagers relative to adults such that selection pressure for acquisition of telomere maintenance mechanism has not yet occurred. The absence of telomerase activation in these tumors may potentially correlate with the less frequent anaplasia and more indolent clinical behavior that has been observed in pediatric oligodendrogliomas compared to their adult counterparts [20]. Table S1. List of the 479 genes targeted for sequencing on the UCSF500 Cancer Panel. Table S2. Pathogenic mutations identified in the three oligodendrogliomas. (XLSX 20 kb) Figure S1. Snapshots from the Integrated Genome Viewer of the IDH mutations present in each of the three oligodendrogliomas, IDH-mutant and 1p/19q-codeleted, in teenagers. Fig. S2. Chromosomal copy number and zygosity plots for the oligodendroglioma, IDHmutant and 1p/19q-codeleted, from teenage patient #2. (PDF 950 kb)
  23 in total

1.  The somatic genomic landscape of chromophobe renal cell carcinoma.

Authors:  Caleb F Davis; Christopher J Ricketts; Min Wang; Lixing Yang; Andrew D Cherniack; Hui Shen; Christian Buhay; Hyojin Kang; Sang Cheol Kim; Catherine C Fahey; Kathryn E Hacker; Gyan Bhanot; Dmitry A Gordenin; Andy Chu; Preethi H Gunaratne; Michael Biehl; Sahil Seth; Benny A Kaipparettu; Christopher A Bristow; Lawrence A Donehower; Eric M Wallen; Angela B Smith; Satish K Tickoo; Pheroze Tamboli; Victor Reuter; Laura S Schmidt; James J Hsieh; Toni K Choueiri; A Ari Hakimi; Lynda Chin; Matthew Meyerson; Raju Kucherlapati; Woong-Yang Park; A Gordon Robertson; Peter W Laird; Elizabeth P Henske; David J Kwiatkowski; Peter J Park; Margaret Morgan; Brian Shuch; Donna Muzny; David A Wheeler; W Marston Linehan; Richard A Gibbs; W Kimryn Rathmell; Chad J Creighton
Journal:  Cancer Cell       Date:  2014-08-21       Impact factor: 31.743

2.  Mutational landscape and clonal architecture in grade II and III gliomas.

Authors:  Hiromichi Suzuki; Kosuke Aoki; Kenichi Chiba; Yusuke Sato; Yusuke Shiozawa; Yuichi Shiraishi; Teppei Shimamura; Atsushi Niida; Kazuya Motomura; Fumiharu Ohka; Takashi Yamamoto; Kuniaki Tanahashi; Melissa Ranjit; Toshihiko Wakabayashi; Tetsuichi Yoshizato; Keisuke Kataoka; Kenichi Yoshida; Yasunobu Nagata; Aiko Sato-Otsubo; Hiroko Tanaka; Masashi Sanada; Yutaka Kondo; Hideo Nakamura; Masahiro Mizoguchi; Tatsuya Abe; Yoshihiro Muragaki; Reiko Watanabe; Ichiro Ito; Satoru Miyano; Atsushi Natsume; Seishi Ogawa
Journal:  Nat Genet       Date:  2015-04-13       Impact factor: 38.330

3.  Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.

Authors:  Daniel J Brat; Roel G W Verhaak; Kenneth D Aldape; W K Alfred Yung; Sofie R Salama; Lee A D Cooper; Esther Rheinbay; C Ryan Miller; Mark Vitucci; Olena Morozova; A Gordon Robertson; Houtan Noushmehr; Peter W Laird; Andrew D Cherniack; Rehan Akbani; Jason T Huse; Giovanni Ciriello; Laila M Poisson; Jill S Barnholtz-Sloan; Mitchel S Berger; Cameron Brennan; Rivka R Colen; Howard Colman; Adam E Flanders; Caterina Giannini; Mia Grifford; Antonio Iavarone; Rajan Jain; Isaac Joseph; Jaegil Kim; Katayoon Kasaian; Tom Mikkelsen; Bradley A Murray; Brian Patrick O'Neill; Lior Pachter; Donald W Parsons; Carrie Sougnez; Erik P Sulman; Scott R Vandenberg; Erwin G Van Meir; Andreas von Deimling; Hailei Zhang; Daniel Crain; Kevin Lau; David Mallery; Scott Morris; Joseph Paulauskis; Robert Penny; Troy Shelton; Mark Sherman; Peggy Yena; Aaron Black; Jay Bowen; Katie Dicostanzo; Julie Gastier-Foster; Kristen M Leraas; Tara M Lichtenberg; Christopher R Pierson; Nilsa C Ramirez; Cynthia Taylor; Stephanie Weaver; Lisa Wise; Erik Zmuda; Tanja Davidsen; John A Demchok; Greg Eley; Martin L Ferguson; Carolyn M Hutter; Kenna R Mills Shaw; Bradley A Ozenberger; Margi Sheth; Heidi J Sofia; Roy Tarnuzzer; Zhining Wang; Liming Yang; Jean Claude Zenklusen; Brenda Ayala; Julien Baboud; Sudha Chudamani; Mark A Jensen; Jia Liu; Todd Pihl; Rohini Raman; Yunhu Wan; Ye Wu; Adrian Ally; J Todd Auman; Miruna Balasundaram; Saianand Balu; Stephen B Baylin; Rameen Beroukhim; Moiz S Bootwalla; Reanne Bowlby; Christopher A Bristow; Denise Brooks; Yaron Butterfield; Rebecca Carlsen; Scott Carter; Lynda Chin; Andy Chu; Eric Chuah; Kristian Cibulskis; Amanda Clarke; Simon G Coetzee; Noreen Dhalla; Tim Fennell; Sheila Fisher; Stacey Gabriel; Gad Getz; Richard Gibbs; Ranabir Guin; Angela Hadjipanayis; D Neil Hayes; Toshinori Hinoue; Katherine Hoadley; Robert A Holt; Alan P Hoyle; Stuart R Jefferys; Steven Jones; Corbin D Jones; Raju Kucherlapati; Phillip H Lai; Eric Lander; Semin Lee; Lee Lichtenstein; Yussanne Ma; Dennis T Maglinte; Harshad S Mahadeshwar; Marco A Marra; Michael Mayo; Shaowu Meng; Matthew L Meyerson; Piotr A Mieczkowski; Richard A Moore; Lisle E Mose; Andrew J Mungall; Angeliki Pantazi; Michael Parfenov; Peter J Park; Joel S Parker; Charles M Perou; Alexei Protopopov; Xiaojia Ren; Jeffrey Roach; Thaís S Sabedot; Jacqueline Schein; Steven E Schumacher; Jonathan G Seidman; Sahil Seth; Hui Shen; Janae V Simons; Payal Sipahimalani; Matthew G Soloway; Xingzhi Song; Huandong Sun; Barbara Tabak; Angela Tam; Donghui Tan; Jiabin Tang; Nina Thiessen; Timothy Triche; David J Van Den Berg; Umadevi Veluvolu; Scot Waring; Daniel J Weisenberger; Matthew D Wilkerson; Tina Wong; Junyuan Wu; Liu Xi; Andrew W Xu; Lixing Yang; Travis I Zack; Jianhua Zhang; B Arman Aksoy; Harindra Arachchi; Chris Benz; Brady Bernard; Daniel Carlin; Juok Cho; Daniel DiCara; Scott Frazer; Gregory N Fuller; JianJiong Gao; Nils Gehlenborg; David Haussler; David I Heiman; Lisa Iype; Anders Jacobsen; Zhenlin Ju; Sol Katzman; Hoon Kim; Theo Knijnenburg; Richard Bailey Kreisberg; Michael S Lawrence; William Lee; Kalle Leinonen; Pei Lin; Shiyun Ling; Wenbin Liu; Yingchun Liu; Yuexin Liu; Yiling Lu; Gordon Mills; Sam Ng; Michael S Noble; Evan Paull; Arvind Rao; Sheila Reynolds; Gordon Saksena; Zack Sanborn; Chris Sander; Nikolaus Schultz; Yasin Senbabaoglu; Ronglai Shen; Ilya Shmulevich; Rileen Sinha; Josh Stuart; S Onur Sumer; Yichao Sun; Natalie Tasman; Barry S Taylor; Doug Voet; Nils Weinhold; John N Weinstein; Da Yang; Kosuke Yoshihara; Siyuan Zheng; Wei Zhang; Lihua Zou; Ty Abel; Sara Sadeghi; Mark L Cohen; Jenny Eschbacher; Eyas M Hattab; Aditya Raghunathan; Matthew J Schniederjan; Dina Aziz; Gene Barnett; Wendi Barrett; Darell D Bigner; Lori Boice; Cathy Brewer; Chiara Calatozzolo; Benito Campos; Carlos Gilberto Carlotti; Timothy A Chan; Lucia Cuppini; Erin Curley; Stefania Cuzzubbo; Karen Devine; Francesco DiMeco; Rebecca Duell; J Bradley Elder; Ashley Fehrenbach; Gaetano Finocchiaro; William Friedman; Jordonna Fulop; Johanna Gardner; Beth Hermes; Christel Herold-Mende; Christine Jungk; Ady Kendler; Norman L Lehman; Eric Lipp; Ouida Liu; Randy Mandt; Mary McGraw; Roger Mclendon; Christopher McPherson; Luciano Neder; Phuong Nguyen; Ardene Noss; Raffaele Nunziata; Quinn T Ostrom; Cheryl Palmer; Alessandro Perin; Bianca Pollo; Alexander Potapov; Olga Potapova; W Kimryn Rathmell; Daniil Rotin; Lisa Scarpace; Cathy Schilero; Kelly Senecal; Kristen Shimmel; Vsevolod Shurkhay; Suzanne Sifri; Rosy Singh; Andrew E Sloan; Kathy Smolenski; Susan M Staugaitis; Ruth Steele; Leigh Thorne; Daniela P C Tirapelli; Andreas Unterberg; Mahitha Vallurupalli; Yun Wang; Ronald Warnick; Felicia Williams; Yingli Wolinsky; Sue Bell; Mara Rosenberg; Chip Stewart; Franklin Huang; Jonna L Grimsby; Amie J Radenbaugh; Jianan Zhang
Journal:  N Engl J Med       Date:  2015-06-10       Impact factor: 91.245

4.  Deep sequencing of WNT-activated medulloblastomas reveals secondary SHH pathway activation.

Authors:  J Bryan Iorgulescu; Jessica Van Ziffle; Meredith Stevers; James P Grenert; Boris C Bastian; Lukas Chavez; Damian Stichel; Ivo Buchhalter; David Samuel; Theodore Nicolaides; Anuradha Banerjee; Sabine Mueller; Nalin Gupta; Tarik Tihan; Andrew W Bollen; Paul A Northcott; Marcel Kool; Stefan Pfister; Andrey Korshunov; Arie Perry; David A Solomon
Journal:  Acta Neuropathol       Date:  2018-02-12       Impact factor: 17.088

5.  Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system.

Authors:  Christian Koelsche; Felix Sahm; David Capper; David Reuss; Dominik Sturm; David T W Jones; Marcel Kool; Paul A Northcott; Benedikt Wiestler; Katja Böhmer; Jochen Meyer; Christian Mawrin; Christian Hartmann; Michel Mittelbronn; Michael Platten; Benjamin Brokinkel; Marcel Seiz; Christel Herold-Mende; Andreas Unterberg; Jens Schittenhelm; Michael Weller; Stefan Pfister; Wolfgang Wick; Andrey Korshunov; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2013-10-24       Impact factor: 17.088

6.  Molecular Analysis of Pediatric Oligodendrogliomas Highlights Genetic Differences with Adult Counterparts and Other Pediatric Gliomas.

Authors:  David Nauen; Lisa Haley; Ming-Tseh Lin; Arie Perry; Caterina Giannini; Peter C Burger; Fausto J Rodriguez
Journal:  Brain Pathol       Date:  2015-08-14       Impact factor: 6.508

7.  Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1.

Authors:  Lori A Ramkissoon; Peleg M Horowitz; Justin M Craig; Shakti H Ramkissoon; Benjamin E Rich; Steven E Schumacher; Aaron McKenna; Michael S Lawrence; Guillaume Bergthold; Priscilla K Brastianos; Barbara Tabak; Matthew D Ducar; Paul Van Hummelen; Laura E MacConaill; Tina Pouissant-Young; Yoon-Jae Cho; Hala Taha; Madeha Mahmoud; Daniel C Bowers; Linda Margraf; Uri Tabori; Cynthia Hawkins; Roger J Packer; D Ashley Hill; Scott L Pomeroy; Charles G Eberhart; Ian F Dunn; Liliana Goumnerova; Gad Getz; Jennifer A Chan; Sandro Santagata; William C Hahn; Charles D Stiles; Azra H Ligon; Mark W Kieran; Rameen Beroukhim; Keith L Ligon
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-30       Impact factor: 11.205

8.  Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma.

Authors:  Michele Ceccarelli; Floris P Barthel; Tathiane M Malta; Thais S Sabedot; Sofie R Salama; Bradley A Murray; Olena Morozova; Yulia Newton; Amie Radenbaugh; Stefano M Pagnotta; Samreen Anjum; Jiguang Wang; Ganiraju Manyam; Pietro Zoppoli; Shiyun Ling; Arjun A Rao; Mia Grifford; Andrew D Cherniack; Hailei Zhang; Laila Poisson; Carlos Gilberto Carlotti; Daniela Pretti da Cunha Tirapelli; Arvind Rao; Tom Mikkelsen; Ching C Lau; W K Alfred Yung; Raul Rabadan; Jason Huse; Daniel J Brat; Norman L Lehman; Jill S Barnholtz-Sloan; Siyuan Zheng; Kenneth Hess; Ganesh Rao; Matthew Meyerson; Rameen Beroukhim; Lee Cooper; Rehan Akbani; Margaret Wrensch; David Haussler; Kenneth D Aldape; Peter W Laird; David H Gutmann; Houtan Noushmehr; Antonio Iavarone; Roel G W Verhaak
Journal:  Cell       Date:  2016-01-28       Impact factor: 41.582

9.  The genetic landscape of ganglioglioma.

Authors:  Melike Pekmezci; Javier E Villanueva-Meyer; Benjamin Goode; Jessica Van Ziffle; Courtney Onodera; James P Grenert; Boris C Bastian; Gabriel Chamyan; Ossama M Maher; Ziad Khatib; Bette K Kleinschmidt-DeMasters; David Samuel; Sabine Mueller; Anuradha Banerjee; Jennifer L Clarke; Tabitha Cooney; Joseph Torkildson; Nalin Gupta; Philip Theodosopoulos; Edward F Chang; Mitchel Berger; Andrew W Bollen; Arie Perry; Tarik Tihan; David A Solomon
Journal:  Acta Neuropathol Commun       Date:  2018-06-07       Impact factor: 7.801

10.  A recurrent kinase domain mutation in PRKCA defines chordoid glioma of the third ventricle.

Authors:  Benjamin Goode; Gourish Mondal; Michael Hyun; Diego Garrido Ruiz; Yu-Hsiu Lin; Jessica Van Ziffle; Nancy M Joseph; Courtney Onodera; Eric Talevich; James P Grenert; Iman H Hewedi; Matija Snuderl; Daniel J Brat; Bette K Kleinschmidt-DeMasters; Fausto J Rodriguez; David N Louis; William H Yong; M Beatriz Lopes; Marc K Rosenblum; Nicholas Butowski; Tarik Tihan; Andrew W Bollen; Joanna J Phillips; Arun P Wiita; Iwei Yeh; Matthew P Jacobson; Boris C Bastian; Arie Perry; David A Solomon
Journal:  Nat Commun       Date:  2018-02-23       Impact factor: 14.919

View more
  7 in total

1.  Myxoid glioneuronal tumor, PDGFRA p.K385-mutant: clinical, radiologic, and histopathologic features.

Authors:  Calixto-Hope G Lucas; Javier E Villanueva-Meyer; Nicholas Whipple; Nancy Ann Oberheim Bush; Tabitha Cooney; Susan Chang; Michael McDermott; Mitchel Berger; Elaine Cham; Peter P Sun; Angelica Putnam; Hong Zhou; Robert Bollo; Samuel Cheshier; Matthew M Poppe; Kar-Ming Fung; Sarah Sung; Chad Glenn; Xuemo Fan; Serguei Bannykh; Jethro Hu; Moise Danielpour; Rong Li; Elizabeth Alva; James Johnston; Jessica Van Ziffle; Courtney Onodera; Patrick Devine; James P Grenert; Julieann C Lee; Melike Pekmezci; Tarik Tihan; Andrew W Bollen; Arie Perry; David A Solomon
Journal:  Brain Pathol       Date:  2019-11-06       Impact factor: 6.508

Review 2.  Prognostic significance of TERT promoter mutations in adult-type diffuse gliomas.

Authors:  Hideyuki Arita; Koichi Ichimura
Journal:  Brain Tumor Pathol       Date:  2022-01-31       Impact factor: 3.298

Review 3.  Genes of the Ubiquitin Proteasome System Qualify as Differential Markers in Malignant Glioma of Astrocytic and Oligodendroglial Origin.

Authors:  Jerry Vriend; Thomas Klonisch
Journal:  Cell Mol Neurobiol       Date:  2022-07-27       Impact factor: 4.231

Review 4.  Targeting metabolic dependencies in pediatric cancer.

Authors:  Sameer H Issaq; Christine M Heske
Journal:  Curr Opin Pediatr       Date:  2020-02       Impact factor: 2.856

Review 5.  Epigenomics and immunotherapeutic advances in pediatric brain tumors.

Authors:  Malak Abedalthagafi; Nahla Mobark; May Al-Rashed; Musa AlHarbi
Journal:  NPJ Precis Oncol       Date:  2021-04-30

6.  Gliomas arising in the setting of Li-Fraumeni syndrome stratify into two molecular subgroups with divergent clinicopathologic features.

Authors:  Emily A Sloan; Stephanie Hilz; Rohit Gupta; Cathryn Cadwell; Biswarathan Ramani; Jeffrey Hofmann; Cassie N Kline; Anu Banerjee; Alyssa Reddy; Nancy Ann Oberheim Bush; Susan Chang; Steve Braunstein; Edward F Chang; Corey Raffel; Nalin Gupta; Peter P Sun; John Y H Kim; Gregory Moes; Elizabeth Alva; Rong Li; Carol S Bruggers; Mouied Alashari; Cynthia Wetmore; Shipra Garg; Megan Dishop; Jessica Van Ziffle; Courtney Onodera; Patrick Devine; James P Grenert; Julieann C Lee; Joanna J Phillips; Melike Pekmezci; Tarik Tihan; Andrew W Bollen; Mitchel S Berger; Joseph F Costello; Arie Perry; David A Solomon
Journal:  Acta Neuropathol       Date:  2020-03-10       Impact factor: 15.887

Review 7.  Telomere Maintenance in Pediatric Cancer.

Authors:  Sandra Ackermann; Matthias Fischer
Journal:  Int J Mol Sci       Date:  2019-11-20       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.